Medtronic

Rank: 1
2015 Rank2
Employees92,000
Revenue:$28,833,000,000
R&D Spend:$1,640,000,000
Fiscal year ending:04-24-16
Click here to see all 100

Medtronic made the biggest splash of 2014 when it said it would acquire Covidien in the largest merger medtech has ever seen. Ultimately the price tage for the deal, which closed in January 2015, reached $50 billion. The price tag didn't prevent the world's largest pure-play medtech company from making other acquisitions, including RF Surgical Solutions ($235 million), Aptus Endosystems ($110 million), CardioInsight ($93 million), NGC Medical ($350 million), Visualase ($105 million), Sapiens ($200 million), Corventis (a reported $150 million) and Tyrx ($160 million). Medtronic was responsible for the 2nd-largest headline of last year as well, when it revealed that the expected slam-dunk for its Symplicity renal denervation device instead clanked off the rim. The bad news was balanced by good, in the form of FDA nods for the In.Pact Admiral drug-eluting balloon and the CoreValve transcatheter aortic valve implant, and European approval of its tiny Micra pacemaker. Medtronic also settled its long-running patent infringement beef with Edwards Lifesciences for $750m plus royalties.

Medtronic is working with partners in Russia to address health challenges in the country. The FDA approves the world smallest pacemaker: Medtronic Micra. A special insulation material, named LaRC-SI, was originally created for the harsh environments of space, but it’s also making an impact in the one of the world’s most delicate environments – the human heart. In April, LaRC-SI was inducted into Space Technology Hall of Fame during the Space Foundation’s 32nd Space Symposium. Medtronic scientists were inspired to adapt LaRC-SI for use in implanted leads, or tiny wires, that are implanted in the heart through a vein that carry information signals from the heart to the implanted medical device.

2015 Top 500 Solar Contractors Key Personnel: Omar Ishrak, Chairman & CEO; Michael Coyle, EVP & President, Cardiac & Vascular Group; Gary Ellis, EVP, Global Operations, IT, Facilities & Real Estate; Mike Genau, SVP, President, Americas; Hooman Hakami, EVP, President, Diabetes; Bryan Hanson, EVP, President, Minimally Invasive Therapies; Dr. Rick Kuntz, SVP, Chief Scientific, Clinical, & Regulatory Officer; Chris Lee, SVP, President, Greater China; Brad Lerman, SVP, GC & Secretary; Geoffrey Martha, EVP, President, Restorative Therapies Group; Karen Parkhill, EVP, CFO; Luann Pendy, SVP, Global Quality; Carol Surface, SVP, Chief HR Officer; Rob Ten Hoedt, EVP, President, EMEA; Bob White, SVP & President, APac;

7000 Central Ave
NE Fridley, MN
55432
USA